Croatian cancer care suffers from long waits, limited drug access due to funding, and systemic organizational failures.
🔗 Read the article on balkaninsight.com
[This is an automatically generated summary, for reference only]
A Croatian cancer patient’s experience highlights significant delays in diagnosis and treatment, a pattern echoed by other oncology patients in Croatia. The text points to several systemic issues contributing to high cancer death rates in Croatia, including long waiting times for appointments and scans, and limited availability of advanced cancer drugs.
Key problems include:
- Systemic Delays: Patients frequently face long waits for necessary diagnostic procedures, sometimes requiring them to rely on personal connections to access timely care.
- Drug Access and Funding: While new, effective cancer drugs are approved across the EU, Croatia lags in adoption, partly due to lower per capita spending on cancer treatment compared to other EU nations. The Croatian Health Insurance Fund (HZZO) has a history of rejecting requests for expensive but beneficial new treatments, citing cost.
- Administrative Hurdles: Patients face bureaucratic challenges, such as needing referrals and waiting for expert committee approvals for covered drugs, which can delay treatment.
- Infrastructure and Care Gaps: There is a shortage of general practitioners and logistical difficulties for patients living far from major medical centers.
These issues are compounded by the fact that while private clinics are expanding and receiving government funding, the overall public system struggles with staffing and efficiency.
